Browsing Centre for Molecular Oncology by Title
Now showing items 1-20 of 272
-
Adaptive immunity in cancer immunology and therapeutics.
(2014)The vast genetic alterations characteristic of tumours produce a number of tumour antigens that enable the immune system to differentiate tumour cells from normal cells. Counter to this, tumour cells have developed mechanisms ... -
AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting.
(2019-07-02)Anterior gradient 2 (AGR2), a protein disulfide isomerase, shows two subcellular localizations: intracellular (iAGR2) and extracellular (eAGR2). In healthy cells that express AGR2, the predominant form is iAGR2, which ... -
AKT1-mediated Lamin A/C degradation is required for nuclear degradation and normal epidermal terminal differentiation.
(2015-12)Nuclear degradation is a key stage in keratinocyte terminal differentiation and the formation of the cornified envelope that comprises the majority of epidermal barrier function. Parakeratosis, the retention of nuclear ... -
Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells.
(BioMed Central, 2015-01-16)BACKGROUND: Androgens drive the onset and progression of prostate cancer (PCa) via androgen receptor (AR) signalling. The principal treatment for PCa is androgen deprivation therapy, although the majority of patients ... -
Anesthesia and Monitoring of Animals During MRI Studies.
(2018)The use of imaging represents a major impact on the refinement and the reduction of in vivo studies in animal models, in particular for allowing longitudinal monitoring of the onset and the progression of disease within ... -
The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer
(Impact Journals, 2018-10-09)Pimozide, an antipsychotic drug of the diphenylbutylpiperidine class, has been shown to suppress cell growth of breast cancer cells in vitro. In this study we further explore the inhibitory effects of this molecule in ...
